Clinical Trials · NCT03332797

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Name: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 1Gonadorelin

Phase: Phase 1
Recruitment status: Active Not Recruiting
Sponsor: Genentech, Inc.
Enrollment: 181
Start date: Nov 2017
Locations: 23 sites, 5 countries
Primary endpoint: Number of Participants with Adverse Events by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0)

View Gonadorelin compound reference